Oncobiologics Inc (ONS) 4.48 $ONS Oncobiologics
Post# of 273254
Posted On: 09/23/2016 7:22:20 AM
Oncobiologics Inc (ONS) 4.48 $ONS
Oncobiologics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
GlobeNewswire - Wed Aug 31, 3:48PM CDT
Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and President, Pankaj Mohan, Ph.D., will present at the BioCentury's Annual NewsMakers in the Biotech Industry Conference. The presentation will take place on Friday, September 9, 2016 at 2:30 p.m. ET in room 402/403 of the Millennium Broadway Hotel in New York City.
ONS: 4.48 (+0.07), ONSIU: 4.62 (-0.10)
Oncobiologics Announces First CTA Approvals for Global Phase 3 Clinical Program for ONS-3010 (Humira(R) biosimilar)
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Phase 3 clinical plan for ONS-3010 (Humira(R) biosimilar) has received the first of its European Union (EU) clinical trial authorization (CTA) approvals, including in the United Kingdom, Germany and Spain, for the biosimilarity study portion of the Phase 3 clinical program.
ONS: 4.48 (+0.07), ONSIU: 4.62 (-0.10)
Oncobiologics Announces Pricing of Its Initial Public Offering of Units
PR Newswire - Thu May 12, 5:15PM CDT
Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced the pricing of its initial public offering of 5,833,334 units at a price to the public of $6.00 per unit. Each unit consists of one share of common stock, one-half of a Series A warrant and one-half of a Series B warrant. Each whole Series A warrant entitles the holder to purchase one share of Oncobiologics' common stock at an initial exercise price of $6.60, subject to adjustment. Each whole Series B warrant entitles the holder to purchase one share of Oncobiologics' common stock at an initial exercise price of $8.50, subject to adjustment. Oncobiologics, Inc. also has granted the underwriters a 30-day option to purchase up to an additional 875,000 units at the initial public offering price per unit to cover over-allotments, if any. All of the units are being offered by Oncobiologics, Inc. Concurrently with the offering, Oncobiologics, Inc. is also selling, through a separate private placement, 833,332 units to Sabby Healthcare Master Fund Ltd., an existing stockholder, at the initial public offering price per unit.
ONS: 4.48 (+0.07), ONSIU: 4.62 (-0.10)
Oncobiologics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
GlobeNewswire - Wed Aug 31, 3:48PM CDT
Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and President, Pankaj Mohan, Ph.D., will present at the BioCentury's Annual NewsMakers in the Biotech Industry Conference. The presentation will take place on Friday, September 9, 2016 at 2:30 p.m. ET in room 402/403 of the Millennium Broadway Hotel in New York City.
ONS: 4.48 (+0.07), ONSIU: 4.62 (-0.10)
Oncobiologics Announces First CTA Approvals for Global Phase 3 Clinical Program for ONS-3010 (Humira(R) biosimilar)
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Phase 3 clinical plan for ONS-3010 (Humira(R) biosimilar) has received the first of its European Union (EU) clinical trial authorization (CTA) approvals, including in the United Kingdom, Germany and Spain, for the biosimilarity study portion of the Phase 3 clinical program.
ONS: 4.48 (+0.07), ONSIU: 4.62 (-0.10)
Oncobiologics Announces Pricing of Its Initial Public Offering of Units
PR Newswire - Thu May 12, 5:15PM CDT
Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced the pricing of its initial public offering of 5,833,334 units at a price to the public of $6.00 per unit. Each unit consists of one share of common stock, one-half of a Series A warrant and one-half of a Series B warrant. Each whole Series A warrant entitles the holder to purchase one share of Oncobiologics' common stock at an initial exercise price of $6.60, subject to adjustment. Each whole Series B warrant entitles the holder to purchase one share of Oncobiologics' common stock at an initial exercise price of $8.50, subject to adjustment. Oncobiologics, Inc. also has granted the underwriters a 30-day option to purchase up to an additional 875,000 units at the initial public offering price per unit to cover over-allotments, if any. All of the units are being offered by Oncobiologics, Inc. Concurrently with the offering, Oncobiologics, Inc. is also selling, through a separate private placement, 833,332 units to Sabby Healthcare Master Fund Ltd., an existing stockholder, at the initial public offering price per unit.
ONS: 4.48 (+0.07), ONSIU: 4.62 (-0.10)
(0)
(0)Scroll down for more posts ▼